Cas:68738-97-6 5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol manufacturer & supplier

We serve Chemical Name:5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol CAS:68738-97-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol

Chemical Name:5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol
CAS.NO:68738-97-6
Synonyms:einecs 272-121-9
Molecular Formula:C29H34N2O
Molecular Weight:426.59300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:612.3ºC at 760 mmHg
Density:1.12g/cm3
Index of Refraction:1.615
PSA:30.09000
Exact Mass:426.26700
LogP:7.31060

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like einecs 272-121-9 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,einecs 272-121-9 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,einecs 272-121-9 Use and application,einecs 272-121-9 technical grade,usp/ep/jp grade.


Related News: Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). 5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol manufacturer Patients given the vaccine also experienced a reduction in cerebrospinal fluid biomarkers of abnormal tau, results show. 5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol supplier Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement. 5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 5-[4-[di(indol-1-yl)methyl]cyclohexen-1-yl]-2-methylpentan-2-ol factory Patients given the vaccine also experienced a reduction in cerebrospinal fluid biomarkers of abnormal tau, results show.